📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Scynexis

1.1 - Company Overview

Scynexis Logo

Scynexis

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of drug discovery, development and manufacturing projects focused on antifungal therapeutics, including ibrexafungerp, a novel oral/IV glucan synthase inhibitor for serious and resistant fungal infections; SCY-247, a second-generation broad-spectrum triterpenoid; VVC and RVVC treatments; and the MARIO study evaluating oral step-down after IV echinocandin for invasive candidiasis and candidemia.

Products and services

  • Ibrexafungerp: A novel-class glucan synthase inhibitor antifungal suitable for oral and IV use, delivering broad-spectrum activity against serious fungal infections, including resistant strains
  • MARIO study: A clinical-trial investigating ibrexafungerp as oral step-down therapy following IV echinocandin for invasive candidiasis and candidemia
  • SCY-247: A second-generation triterpenoid with broad-spectrum antifungal activity, showing promise against difficult-to-treat and emerging fungal infections

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Scynexis

NovaDigm Therapeutics Logo

NovaDigm Therapeutics

HQ: United States Website
  • Description: Provider of vaccines that protect patients from contracting fungal and bacterial infections.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NovaDigm Therapeutics company profile →
Marinomed Biotech Logo

Marinomed Biotech

HQ: Austria Website
  • Description: Provider of biopharmaceutical therapies via patent-protected platforms, including MAVIREX-based products against respiratory viruses and the Marinosolv solubilization technology (available for partnerships via Solv4U). Portfolio includes Carragelose, Budesolv, Tacrosolv, and pipeline programs MAM-1004-2 (autoimmune gastritis) and MAM-1001-4 nasal spray.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Marinomed Biotech company profile →
Resistell Logo

Resistell

HQ: Switzerland Website
  • Description: Provider of antibiotic resistance testing via Phenotech Multistar, an ultra-rapid Antibiotic Susceptibility Testing (AST) platform using nanomotion technology to deliver results in 2 hours independent of bacterial growth, and Phenotech Research, a research device measuring nanoscale cellular vibrations to study growth phenotypes and provide rapid test results.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Resistell company profile →
Spectrum Antimicrobials Logo

Spectrum Antimicrobials

HQ: United States Website
  • Description: Provider of pharmaceutical drug development specializing in antibiotics and therapeutics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Spectrum Antimicrobials company profile →
Anacor Pharmaceuticals Logo

Anacor Pharmaceuticals

HQ: United States Website
  • Description: Provider of small-molecule therapeutics based on a boron chemistry platform, focused on developing topical treatments for fungal, bacterial, and inflammatory diseases, including its primary product candidate AN2690, a novel topical antifungal.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Anacor Pharmaceuticals company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Scynexis

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Scynexis

2.2 - Growth funds investing in similar companies to Scynexis

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Scynexis

4.2 - Public trading comparable groups for Scynexis

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Scynexis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Scynexis

What does Scynexis do?

Scynexis is a provider of drug discovery, development and manufacturing projects focused on antifungal therapeutics, including ibrexafungerp, a novel oral/IV glucan synthase inhibitor for serious and resistant fungal infections; SCY-247, a second-generation broad-spectrum triterpenoid; VVC and RVVC treatments; and the MARIO study evaluating oral step-down after IV echinocandin for invasive candidiasis and candidemia.

Who are Scynexis's competitors?

Scynexis's competitors and similar companies include NovaDigm Therapeutics, Marinomed Biotech, Resistell, Spectrum Antimicrobials, and Anacor Pharmaceuticals.

Where is Scynexis headquartered?

Scynexis is headquartered in United States.

How many employees does Scynexis have?

Scynexis has 1,000 employees 🔒.

When was Scynexis founded?

Scynexis was founded in 2010 🔒.

What sector and industry vertical is Scynexis in?

Scynexis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Scynexis

Who are the top strategic acquirers in Scynexis's sector and industry

Top strategic M&A buyers and acquirers in Scynexis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Scynexis?

Top strategic M&A buyers groups and sectors for Scynexis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Scynexis's sector and industry vertical

Which are the top PE firms investing in Scynexis's sector and industry vertical?

Top PE firms investing in Scynexis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Scynexis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Scynexis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Scynexis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Scynexis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Scynexis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Scynexis?

The key public trading comparables and valuation benchmarks for Scynexis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Scynexis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Scynexis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Scynexis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Scynexis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Scynexis's' sector and industry vertical?

Access recent funding rounds and capital raises in Scynexis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Scynexis